AU760140B2 - Nutritional supplement for cerebral metabolic insufficiencies - Google Patents

Nutritional supplement for cerebral metabolic insufficiencies Download PDF

Info

Publication number
AU760140B2
AU760140B2 AU92139/98A AU9213998A AU760140B2 AU 760140 B2 AU760140 B2 AU 760140B2 AU 92139/98 A AU92139/98 A AU 92139/98A AU 9213998 A AU9213998 A AU 9213998A AU 760140 B2 AU760140 B2 AU 760140B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
acid
mixtures
group
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU92139/98A
Other languages
English (en)
Other versions
AU9213998A (en
Inventor
John P. Blass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU9213998A publication Critical patent/AU9213998A/en
Assigned to BLASS, JOHN P. reassignment BLASS, JOHN P. Alteration of Name(s) of Applicant(s) under S113 Assignors: CORNELL RESEARCH FOUNDATION INC.
Application granted granted Critical
Publication of AU760140B2 publication Critical patent/AU760140B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU92139/98A 1997-10-24 1998-09-01 Nutritional supplement for cerebral metabolic insufficiencies Ceased AU760140B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6316597P 1997-10-24 1997-10-24
US60/063165 1997-10-24
PCT/US1998/018120 WO1999021565A1 (en) 1997-10-24 1998-09-01 Nutritional supplement for cerebral metabolic insufficiencies

Publications (2)

Publication Number Publication Date
AU9213998A AU9213998A (en) 1999-05-17
AU760140B2 true AU760140B2 (en) 2003-05-08

Family

ID=22047375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU92139/98A Ceased AU760140B2 (en) 1997-10-24 1998-09-01 Nutritional supplement for cerebral metabolic insufficiencies

Country Status (7)

Country Link
US (2) US6537969B1 (https=)
EP (1) EP1032403B1 (https=)
JP (2) JP2001521002A (https=)
AT (1) ATE555780T1 (https=)
AU (1) AU760140B2 (https=)
CA (1) CA2306875C (https=)
WO (1) WO1999021565A1 (https=)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4151996A (en) * 1994-11-08 1996-05-31 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
US20050245612A1 (en) * 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
CA2327095A1 (en) * 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
US20060128671A1 (en) * 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE19932197A1 (de) * 1999-07-09 2001-01-18 Neudecker Birgit Topisch anzuwendendes Mittel mit schützender und regenerativer Wirkung
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
HU230252B1 (hu) 2001-01-12 2015-11-30 Biogen Idec International Gmbh Fumársav-amid származékok
SK11252003A3 (sk) * 2001-02-14 2003-12-02 Matthias Rath Kompozície biochemických zlúčenín zúčastňujúcich sa bioenergetického metabolizmu buniek a ich použitie
EP1455826A2 (en) * 2001-12-21 2004-09-15 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment of multiple sclerosis
EP1475090A4 (en) * 2002-02-14 2007-08-08 Ajinomoto Kk DRUG AGAINST MITOCHONDRIAL DISEASES
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
US20040126366A1 (en) * 2002-06-04 2004-07-01 Rima Kaddurah-Daouk Methods of treating cognitive dysfunction by modulating brain energy metabolism
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
EP2561889A3 (en) * 2002-08-01 2013-04-03 Yeda Research and Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
AU2003272728A1 (en) * 2002-09-27 2004-04-19 Children's Medical Center Corporation Methods and compositions for treatment of neurological disorder
SE0301947D0 (sv) * 2003-07-01 2003-07-01 Gramineer Internat Ab New method and uses
RU2360671C2 (ru) * 2003-07-01 2009-07-10 Эссентис Аб Применение альфа-кетоглутаровой кислоты для лечения недостаточности питания или состояния с высоким уровнем глюкозы в плазме
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
CA2529510A1 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
SI1663197T1 (sl) 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006007411A2 (en) * 2004-06-16 2006-01-19 President And Fellows Of Harvard College Methods and compositions for modulating bax-mediated apoptosis
PL368572A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US20060024385A1 (en) * 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
PL369552A1 (pl) * 2004-08-12 2006-02-20 Sgp & Sons Ab Preparat farmaceutyczny lub/i żywieniowy lub/i laboratoryjny wzmagający, wspomagający funkcjonowanie komórek nerwowych i układu nerwowego oraz zastosowanie preparatu farmaceutycznego lub/i żywieniowego w procesie ochrony funkcji układu nerwowego oraz zastosowanie preparatu do ochrony wzrostu stymulacji namnażania i zapobiegania apoptozie komórek nerwowych
WO2006025247A1 (ja) * 2004-08-30 2006-03-09 Kaneka Corporation ミトコンドリア賦活剤
ES2510690T3 (es) * 2004-12-17 2014-10-21 Alan B. Cash Método para extender la esperanza de vida y retrasar la aparición de enfermedad relacionada con la edad
JP2008524123A (ja) * 2004-12-21 2008-07-10 クリティカル ケア コネクションズ インク 治療用栄養組成物又は組合せ、及びそれらの使用方法
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
AU2006239560B2 (en) * 2005-04-28 2010-03-25 Unilever Plc Peptides having an ace inhibiting effect
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1906995A2 (en) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. Adjuvation through cross- structure
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
CA2615028A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-.beta. structure binding compounds
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
JP2007023010A (ja) * 2005-07-19 2007-02-01 Toshiro Azegami 閉経後のホルモンバランス調整及びパーキンソン症の予防改善目的の経口組成物
DE102005035917A1 (de) * 2005-07-28 2007-02-01 November Ag Verwendung von Isocitrat, Isocitronensäure oder einem Derivat davon zur Herstellung eines Medikaments
CN101232822B (zh) 2005-07-29 2012-11-14 蒂马基金会 用于减缓乙醇代谢和用于降低乙醇诱导的疾病风险的组合物
EP2468272A1 (en) * 2006-05-11 2012-06-27 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US8435547B2 (en) * 2006-08-30 2013-05-07 John P. Blass Cream for stimulating mitochondrial activity in the skin
EP2680006A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
SI2139467T1 (sl) * 2007-02-08 2017-01-31 Biogen Ma Inc. Zaščita živčevja pri demielinizacijskih obolenjih
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
US20090269796A1 (en) * 2007-12-05 2009-10-29 The General Hospital Corporation Methods of detecting and treating myocardial ischemia and myocardial infarction
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
FI3398594T3 (en) 2012-09-19 2024-09-23 Grespo Ab Compositions for improvement of brain function
US20140243400A1 (en) * 2013-02-28 2014-08-28 University of Alaska Anchorage Compositions comprising citric acid and malic acid and methods and uses thereof
CA2940871C (en) 2013-03-13 2020-10-20 Genetic Disease Investigators, LLC Methods and compositions for correction of organ dysfunction
US10238673B2 (en) 2013-03-13 2019-03-26 Genetic Disease Investigators, LLC Methods and compositions for treatment of dry eye and correction of organ dysfunctions
GB201411937D0 (en) 2014-07-03 2014-08-20 Medical Res Council Succinate dehydrogenase inhibitors (SDH's)
JP6831558B2 (ja) * 2016-08-23 2021-02-17 株式会社Ｈｂｃフナト 脳機能改善組成物
WO2018057737A1 (en) 2016-09-22 2018-03-29 Cash Alan B Method to alleviate the symptoms of pms
JP6129395B1 (ja) * 2016-10-29 2017-05-17 誠一 荒木 ミトコンドリア活性化に起因した血管内皮細胞保護回復用還元型ビタミンｂ２製剤
IT201700087359A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201800006725A1 (it) * 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
CA3113071A1 (en) * 2018-10-11 2020-04-16 Imbria Pharmaceuticals, Inc. Tca cycle intermediates and methods of use thereof
WO2020086733A1 (en) * 2018-10-24 2020-04-30 Ponce De Leon Health Designated Activity Company Nicotinamide riboside compositions for healthspan extension
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
CN118976034A (zh) * 2021-02-05 2024-11-19 沈阳糖化药物研究有限公司 一种用于动物模型中诱导癌症的组合物及其用途
CN115212195B (zh) * 2022-06-17 2024-02-27 重庆医科大学 苹果酸在制备预防和/或治疗抑郁症的药物中的用途
US20250221952A1 (en) * 2025-03-14 2025-07-10 Louis Dischler Methods and compositions for large modifications of atp output by inner mitochondrial membrane latching

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963579A (en) * 1973-10-17 1976-06-15 Sanraku-Ocean Co., Ltd. Microbiological process for the production of pepstatins
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089985A (en) * 1974-11-11 1978-05-16 Wolff H Ezra Papaya juice product and process
DE2502735B2 (de) * 1975-01-23 1978-11-23 J. Pfrimmer & Co, 8520 Erlangen Verwendung von Glycerophosphaten
BE867467A (fr) * 1977-04-11 1978-11-27 Dow Chemical Co Aliments pour animaux contenant de l'acide malique ou un sel de ce dernier
US4975217A (en) * 1981-07-20 1990-12-04 Kimberly-Clark Corporation Virucidal composition, the method of use and the product therefor
US5185161A (en) * 1984-03-21 1993-02-09 Alcide Corporation Disinfection method and composition therefor
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB8617482D0 (en) * 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
EP0331620B1 (de) 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
AT397201B (de) 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
ATE107643T1 (de) * 1989-05-05 1994-07-15 Asta Medica Ag Salze des azelastins mit verbesserter löslichkeit.
US5188861A (en) * 1990-05-31 1993-02-23 Royal Domaine Inc. Process for preparing a dried fruit product
US5380721A (en) * 1990-09-10 1995-01-10 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
GB9215746D0 (en) 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
FR2709982B1 (fr) * 1993-09-15 1995-12-08 Oreal Emulsions acides stables de type huile-dans-eau et compositions les contenant.
JP3645580B2 (ja) 1993-10-22 2005-05-11 株式会社フジモト・ブラザーズ グルコースエステル誘導体を含有する脳代謝改善剤
JP3663213B2 (ja) * 1995-06-07 2005-06-22 チェイル ジェダン コーポレーション 薬効が増強された加工薬用人参
KR100192678B1 (ko) * 1995-06-07 1999-06-15 손경식 약효가 증강된 가공인삼 제품
AU720643B2 (en) * 1996-08-13 2000-06-08 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
US20050245612A1 (en) * 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
FR2777186B1 (fr) * 1998-04-10 2001-03-09 Oreal Utilisation d'au moins un hydroxystilbene dans une composition raffermissante

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963579A (en) * 1973-10-17 1976-06-15 Sanraku-Ocean Co., Ltd. Microbiological process for the production of pepstatins
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUFT.R (1994) PROC.NATL.ACAD.SCI.USA 91(19) 8731-8738 *

Also Published As

Publication number Publication date
JP2010189432A (ja) 2010-09-02
US6537969B1 (en) 2003-03-25
WO1999021565A1 (en) 1999-05-06
EP1032403B1 (en) 2012-05-02
ATE555780T1 (de) 2012-05-15
US20030176365A1 (en) 2003-09-18
EP1032403A4 (en) 2004-03-31
CA2306875C (en) 2011-01-04
JP2001521002A (ja) 2001-11-06
EP1032403A1 (en) 2000-09-06
AU9213998A (en) 1999-05-17
CA2306875A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
AU760140B2 (en) Nutritional supplement for cerebral metabolic insufficiencies
KR102804813B1 (ko) 세포 생존력을 향상시키기 위한 조성물 및 이의 사용 방법
US20060281691A1 (en) Method of treating obesity
US6498247B2 (en) Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions
CA2816595C (en) Combination therapy for the treatment of depression and other non-infectious diseases
JP2000508318A (ja) 神経細胞の保護方法
US20230165817A1 (en) Dopaminergic mimetics
Blanchet Antipsychotic drug-induced movement disorders
US20040229908A1 (en) Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
Sheard Clinical pharmacology of aggressive behavior
AU2024202516A1 (en) Pharmaceutical combination and its use for treating synucleinopathies
US12083091B2 (en) Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
Ekundayo et al. Management of Alzheimer's disease and related neurotoxic pathologies: Role of thiamine, pyridoxine and cobalamin
CN1652791A (zh) 认知能力的协同增效作用
JPH1045582A (ja) アルツハイマー病の早期発病患者を治療するためのカルニチン誘導体を含む医薬
US20150328230A1 (en) Clearance of amyloid beta
Giri et al. Combinatorial therapy in Alzheimer's disease
JP7298919B2 (ja) ミエリン形成を促進するための組成物
WO2019052629A1 (en) LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
CA2368850C (en) Methods for the prevention and/or the treatment of glutamate cytotoxicity
CA3096453C (en) Pharmaceutical combination comprising fluoxetine and pramipexole and its use for treating synucleinopathies

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JOHN P. BLASS

Free format text: THE FORMER OWNER WAS: CORNELL RESEARCH FOUNDATION, INC.

FGA Letters patent sealed or granted (standard patent)